دورية أكاديمية
Effects of neoadjuvant stereotactic body radiotherapy plus adebrelimab and chemotherapy for triple-negative breast cancer: A pilot study
| العنوان: | Effects of neoadjuvant stereotactic body radiotherapy plus adebrelimab and chemotherapy for triple-negative breast cancer: A pilot study |
|---|---|
| المؤلفون: | Guanglei Chen, Xi Gu, Jinqi Xue, Xu Zhang, Xiaopeng Yu, Yu Zhang, Ailin Li, Yi Zhao, Guijin He, Meiyue Tang, Fei Xing, Jianqiao Yin, Xiaobo Bian, Ye Han, Shuo Cao, Chao Liu, Xiaofan Jiang, Keliang Zhang, Yan Xia, Huajun Li, Nan Niu, Caigang Liu, On behalf of the Northeastern Clinical Research Alliance of Oncology (NCRAO) |
| المصدر: | eLife, Vol 12 (2023) |
| بيانات النشر: | eLife Sciences Publications Ltd, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Medicine LCC:Science LCC:Biology (General) |
| مصطلحات موضوعية: | breast cancer, immunotherapy, radiotherapy, neoadjuvant treatment, Medicine, Science, Biology (General), QH301-705.5 |
| الوصف: | Background: Emerging data have supported the immunostimulatory role of radiotherapy, which could exert a synergistic effect with immune checkpoint inhibitors (ICIs). With proven effective but suboptimal effect of ICI and chemotherapy in triple-negative breast cancer (TNBC), we designed a pilot study to explore the efficacy and safety of neoadjuvant stereotactic body radiotherapy (SBRT) plus adebrelimab and chemotherapy in TNBC patients. Methods: Treatment-naïve TNBC patients received two cycles of intravenous adebrelimab (20 mg/kg, every 3 weeks), and SBRT (24 Gy/3 f, every other day) started at the second cycle, then followed by six cycles of adebrelimab plus nab-paclitaxel (125 mg/m² on days 1 and 8) and carboplatin (area under the curve 6 mg/mL per min on day 1) every 3 weeks. The surgery was performed within 3–5 weeks after the end of neoadjuvant therapy. Primary endpoint was pathological complete response (pCR, ypT0/is ypN0). Secondary endpoints included objective response rate (ORR), residual cancer burden (RCB) 0-I, and safety. Results: 13 patients were enrolled and received at least one dose of therapy. 10 (76.9%) patients completed SBRT and were included in efficacy analysis. 90% (9/10) of patients achieved pCR, both RCB 0-I and ORR reached 100% with three patients achieved complete remission. Adverse events (AEs) of all-grade and grade 3–4 occurred in 92.3% and 53.8%, respectively. One (7.7%) patient had treatment-related serious AEs. No radiation-related dermatitis or death occurred. Conclusions: Adding SBRT to adebrelimab and neoadjuvant chemotherapy led to a substantial proportion of pCR with acceptable toxicities, supporting further exploration of this combination in TNBC patients. Funding: None. Clinical trial number: NCT05132790. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2050-084X |
| Relation: | https://elifesciences.org/articles/91737; https://doaj.org/toc/2050-084X |
| DOI: | 10.7554/eLife.91737 |
| URL الوصول: | https://doaj.org/article/4d40ffdb0c304d388f1adabf0f97596c |
| رقم الأكسشن: | edsdoj.4d40ffdb0c304d388f1adabf0f97596c |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 2050084X |
|---|---|
| DOI: | 10.7554/eLife.91737 |